{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T18:34:25Z","timestamp":1789929265018,"version":"4.0.1"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2013,3,14]],"date-time":"2013-03-14T00:00:00Z","timestamp":1363219200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Appl Health Econ Health Policy"],"published-print":{"date-parts":[[2013,4]]},"DOI":"10.1007\/s40258-013-0016-2","type":"journal-article","created":{"date-parts":[[2013,3,13]],"date-time":"2013-03-13T08:47:57Z","timestamp":1363164477000},"page":"95-106","source":"Crossref","is-referenced-by-count":47,"title":["The Cost Effectiveness of Long-Acting\/Extended-Release Antipsychotics for the Treatment of Schizophrenia"],"prefix":"10.1007","volume":"11","author":[{"given":"Evanthia","family":"Achilla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"McCrone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,3,14]]},"reference":[{"key":"16_CR1","unstructured":"World Health Organization (WHO). The global burden of disease: 2004 update. 2008 [online]. http:\/\/www.who.int\/healthinfo\/global_burden_disease\/estimates_regional\/en\/index.html . Accessed 15 May 2012."},{"issue":"5","key":"16_CR2","doi-asserted-by":"crossref","first-page":"e141","DOI":"10.1371\/journal.pmed.0020141","volume":"2","author":"S Saha","year":"2005","unstructured":"Saha S, Chant D, Welham J, et al. A systematic review of the prevalence of schizophrenia. PLoS Med. 2005;2(5):e141.","journal-title":"PLoS Med"},{"key":"16_CR3","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1741-7015-2-13","volume":"2","author":"J McGrath","year":"2004","unstructured":"McGrath J, Saha S, Welham J, et al. A systematic review of the incidence of schizophrenia: the distribution of rates and the influence of sex, urbanicity, migrant status and methodology. BMC Med. 2004;2:13.","journal-title":"BMC Med"},{"issue":"2","key":"16_CR4","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1093\/oxfordjournals.schbul.a007078","volume":"30","author":"M Knapp","year":"2004","unstructured":"Knapp M, Mangalore R, Simon J. The global costs of schizophrenia. Schizophr Bull. 2004;30(2):279\u201393.","journal-title":"Schizophr Bull"},{"issue":"Suppl. 2","key":"16_CR5","first-page":"1","volume":"161","author":"American Psychiatric Association","year":"2004","unstructured":"American Psychiatric Association. Practice guideline for the treatment of patients with schizophrenia. Am J Psychiatry. 2004;161(Suppl. 2):1\u201356.","journal-title":"Am J Psychiatry"},{"issue":"10","key":"16_CR6","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1001\/archpsyc.63.10.1079","volume":"63","author":"PB Jones","year":"2006","unstructured":"Jones PB, Barnes TR, Davies L, et al. Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry. 2006;63(10):1079\u201387.","journal-title":"Arch Gen Psychiatry"},{"issue":"9369","key":"16_CR7","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1016\/S0140-6736(03)13306-5","volume":"361","author":"S Leucht","year":"2003","unstructured":"Leucht S, Wahlbeck K, Hamann J, et al. New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet. 2003;361(9369):1581\u20139.","journal-title":"Lancet"},{"key":"16_CR8","unstructured":"National Institute for Health and Clinical Excellence (NICE). National Clinical Guideline 82 on core interventions in the treatment and management of schizophrenia in adults in primary and secondary care [updated edition 2009]. http:\/\/publications.nice.org.uk\/schizophrenia-cg82 . Accessed 15 Apr 2012."},{"issue":"12","key":"16_CR9","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","volume":"353","author":"JA Lieberman","year":"2005","unstructured":"Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353(12):1209\u201323.","journal-title":"N Engl J Med"},{"key":"16_CR10","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1192\/bjp.184.4.346","volume":"184","author":"S Almond","year":"2004","unstructured":"Almond S, Knapp M, Francois C, et al. Relapse in schizophrenia: costs, clinical outcomes and quality of life. Br J Psychiatry. 2004;184:346\u201351.","journal-title":"Br J Psychiatry"},{"issue":"Suppl. 8","key":"16_CR11","first-page":"s254","volume":"11","author":"AT Joyce","year":"2005","unstructured":"Joyce AT, Harrison DJ, Loebel AD, et al. Impact of atypical antipsychotics on outcomes of care in schizophrenia. Am J Manag Care. 2005;11(Suppl. 8):s254\u201361.","journal-title":"Am J Manag Care"},{"issue":"7","key":"16_CR12","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1111\/j.1524-4733.2008.00344.x","volume":"11","author":"B Heeg","year":"2008","unstructured":"Heeg B, Buskens E, Botteman M, et al. The cost-effectiveness of atypicals in the UK. Value Health. 2008;11(7):1007\u201321.","journal-title":"Value Health"},{"issue":"Suppl. 4","key":"16_CR13","doi-asserted-by":"crossref","first-page":"s17","DOI":"10.1093\/ajhp\/55.suppl_4.S17","volume":"55","author":"DB Moore","year":"1998","unstructured":"Moore DB, Kelly DL, Sherr JD, et al. Rehospitalization rates for depot antipsychotics and pharmacoeconomic implications: comparison with risperidone. Am J Health Syst Pharm. 1998;55(Suppl. 4):s17\u20139.","journal-title":"Am J Health Syst Pharm"},{"issue":"Suppl. 1","key":"16_CR14","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2165\/00019053-200523001-00002","volume":"23","author":"A Haycox","year":"2005","unstructured":"Haycox A. Pharmacoeconomics of long-acting risperidone: results and validity of cost-effectiveness models. Pharmacoeconomics. 2005;23(Suppl. 1):3\u201316.","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"16_CR15","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1586\/14737175.9.1.9","volume":"9","author":"S Keith","year":"2009","unstructured":"Keith S. Use of long-acting risperidone in psychiatric disorders: focus on efficacy, safety and cost-effectiveness. Expert Rev Neurother. 2009;9(1):9\u201331.","journal-title":"Expert Rev Neurother"},{"issue":"10","key":"16_CR16","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.4088\/JCP.v64n1017","volume":"64","author":"WW Fleischhacker","year":"2003","unstructured":"Fleischhacker WW, Eerdekens M, Karcher K, et al. Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic. J Clin Psychiatry. 2003;64(10):1250\u20137.","journal-title":"J Clin Psychiatry"},{"issue":"Suppl. 1","key":"16_CR17","doi-asserted-by":"crossref","first-page":"62","DOI":"10.2165\/00019053-200523001-00006","volume":"23","author":"PS Chue","year":"2005","unstructured":"Chue PS, Heeg B, Buskens E, et al. Modelling the impact of compliance on the costs and effects of long-acting risperidone in Canada. Pharmacoeconomics. 2005;23(Suppl. 1):62\u201374.","journal-title":"Pharmacoeconomics"},{"key":"16_CR18","doi-asserted-by":"crossref","first-page":"137","DOI":"10.3111\/200104137156","volume":"4","author":"PI Oh","year":"2001","unstructured":"Oh PI, Lanctot KL, Mittmann N, et al. Cost-utility of risperidone compared with standard conventional antipsychotics in chronic schizophrenia. J Med Econ. 2001;4:137\u201356.","journal-title":"J Med Econ"},{"issue":"Suppl. 1","key":"16_CR19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00019053-200523001-00001","volume":"23","author":"L Annemans","year":"2005","unstructured":"Annemans L. Cost effectiveness of long-acting risperidone: what can pharmacoeconomic models teach us? Pharmacoeconomics. 2005;23(Suppl. 1):1\u20132.","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"16_CR20","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.2147\/nedt.2007.3.1.13","volume":"3","author":"P Chue","year":"2007","unstructured":"Chue P. Long-acting risperidone injection: efficacy, safety, and cost-effectiveness of the first long-acting atypical antipsychotic. Neuropsychiatr Dis Treat. 2007;3(1):2007\u201339.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"16_CR21","doi-asserted-by":"crossref","first-page":"s29","DOI":"10.1192\/bjp.195.52.s29","volume":"52","author":"WW Fleischhacker","year":"2009","unstructured":"Fleischhacker WW. Second-generation antipsychotic long-acting injections: systematic review. Br J Psychiatry. 2009;52:s29\u201336.","journal-title":"Br J Psychiatry"},{"issue":"4","key":"16_CR22","first-page":"199","volume":"7","author":"G Bartko","year":"2005","unstructured":"Bartko G, Feher L. Pharmacoeconomic review of the use of injectable long-acting risperidone [Hungarian]. Neuropsychopharmacol Hung. 2005;7(4):199\u2013207.","journal-title":"Neuropsychopharmacol Hung"},{"issue":"2","key":"16_CR23","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0924-977X(03)00109-3","volume":"14","author":"NH Bhanji","year":"2004","unstructured":"Bhanji NH, Chouinard G, Margolese HC. A review of compliance, depot intramuscular antipsychotics and the new long-acting injectable atypical antipsychotic risperidone in schizophrenia. Eur Neuropsychopharmacol. 2004;14(2):87\u201392.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"2","key":"16_CR24","doi-asserted-by":"crossref","first-page":"107","DOI":"10.2165\/00115677-200614020-00006","volume":"14","author":"MP Curran","year":"2006","unstructured":"Curran MP, Keating GM. Management of schizophrenia: defining the role of long-acting injectable risperidone. Dis Manag Health Outcomes. 2006;14(2):107\u201325.","journal-title":"Dis Manag Health Outcomes"},{"issue":"3","key":"16_CR25","doi-asserted-by":"crossref","first-page":"L207","DOI":"10.2165\/00137696-200402030-00005","volume":"2","author":"TS Harrison","year":"2004","unstructured":"Harrison TS, Goa KL. Spotlight on long-acting risperidone in schizophrenia. Am J Drug Deliv. 2004;2(3):L207\u201310.","journal-title":"Am J Drug Deliv"},{"key":"16_CR26","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1093\/ajhp\/61.17.1792","volume":"61","author":"RC Love","year":"2004","unstructured":"Love RC, Conley RJ. Long-acting risperidone injection. Am J Health Syst Pharm. 2004;61:1792\u2013800.","journal-title":"Am J Health Syst Pharm"},{"issue":"1","key":"16_CR27","first-page":"54","volume":"9","author":"M Purgato","year":"2011","unstructured":"Purgato M, Adams CE. Bromperidol decanoate (depot) for schizophrenia. Cochrane Database Syst Rev. 2011;9(1):54.","journal-title":"Cochrane Database Syst Rev"},{"issue":"Suppl. 1","key":"16_CR28","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2165\/00019053-200523001-00004","volume":"23","author":"D Graeve De","year":"2005","unstructured":"De Graeve D, Smet A, Mehnert A, et al. Long-acting risperidone compared with oral olanzapine and haloperidol depot in schizophrenia: a Belgian cost-effectiveness analysis. Pharmacoeconomics. 2005;23(Suppl. 1):35\u201347.","journal-title":"Pharmacoeconomics"},{"issue":"5","key":"16_CR29","doi-asserted-by":"crossref","first-page":"327","DOI":"10.2165\/11536180-000000000-00000","volume":"8","author":"M Hensen","year":"2010","unstructured":"Hensen M, Heeg B, Lthgren M, et al. Cost effectiveness of long-acting risperidone in Sweden. Appl Health Econ Health Policy. 2010;8(5):327\u201341.","journal-title":"Appl Health Econ Health Policy"},{"key":"16_CR30","doi-asserted-by":"crossref","first-page":"49","DOI":"10.2165\/00019053-200523001-00005","volume":"23","author":"G Laux","year":"2005","unstructured":"Laux G, Heeg B, van Hout BA, et al. Costs and effects of long-acting risperidone compared with oral atypical and conventional depot formulations in Germany. Pharmacoeconomics. 2005;23:49\u201361.","journal-title":"Pharmacoeconomics"},{"issue":"2","key":"16_CR31","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0013-7006(05)82390-5","volume":"31","author":"PM Llorca","year":"2005","unstructured":"Llorca PM, Miadi-Fargier H, Lancon C, et al. Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation [French]. Encephale. 2005;31(2):235\u201346.","journal-title":"Encephale"},{"issue":"4","key":"16_CR32","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1111\/j.1440-1819.2005.01390.x","volume":"59","author":"YK Yang","year":"2005","unstructured":"Yang YK, Tarn YH, Wang TY, et al. Pharmacoeconomic evaluation of schizophrenia in Taiwan: model comparison of long-acting risperidone versus olanzapine versus depot haloperidol based on estimated costs. Psychiatry Clin Neurosci. 2005;59(4):385\u201394.","journal-title":"Psychiatry Clin Neurosci"},{"issue":"3","key":"16_CR33","doi-asserted-by":"crossref","first-page":"299","DOI":"10.2165\/00019053-200523030-00009","volume":"23","author":"NC Edwards","year":"2005","unstructured":"Edwards NC, Rupnow MFT, Pashos CL, et al. Cost-effectiveness model of long-acting risperidone in schizophrenia in the US. Pharmacoeconomics. 2005;23(3):299\u2013314.","journal-title":"Pharmacoeconomics"},{"issue":"Suppl. 1","key":"16_CR34","doi-asserted-by":"crossref","first-page":"75","DOI":"10.2165\/00019053-200523001-00007","volume":"23","author":"NC Edwards","year":"2005","unstructured":"Edwards NC, Locklear JC, Rupnow MF, et al. Cost effectiveness of long-acting risperidone injection versus alternative antipsychotic agents in patients with schizophrenia in the USA. Pharmacoeconomics. 2005;23(Suppl. 1):75\u201389.","journal-title":"Pharmacoeconomics"},{"issue":"Suppl. 3","key":"16_CR35","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/j.1524-4733.2009.00630.x","volume":"12","author":"L Yang","year":"2009","unstructured":"Yang L, Li M, Tao LB, et al. Cost-effectiveness of long-acting risperidone injection versus alternative atypical antipsychotic agents in patients with schizophrenia in China. Value Health. 2009;12(Suppl. 3):66\u20139.","journal-title":"Value Health"},{"issue":"2","key":"16_CR36","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1185\/030079907X253834","volume":"24","author":"BM Heeg","year":"2008","unstructured":"Heeg BM, Antunes J, Figueira ML, et al. Cost-effectiveness and budget impact of long-acting risperidone in Portugal: a modeling exercise. Curr Med Res Opin. 2008;24(2):349\u201358.","journal-title":"Curr Med Res Opin"},{"key":"16_CR37","doi-asserted-by":"crossref","unstructured":"Mantovani LG, Berto P, D\u2019 Ausilio A, et al. Costs and effects of Long Acting Risperidone (LAR) versus atypical antipsychotics in the treatment of schizophrenic subjects in Italy. Farmeconomia e percorsi terapeutici 2004;5(1):5\u201311.","DOI":"10.7175\/fe.v5i1.782"},{"issue":"12","key":"16_CR38","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1111\/j.1742-1241.2007.01431.x","volume":"61","author":"M Obradovic","year":"2007","unstructured":"Obradovic M, Mrhar A, Kos M. Cost-effectiveness of antipsychotics for outpatients with chronic schizophrenia. Int J Clin Pract. 2007;61(12):1979\u201388.","journal-title":"Int J Clin Pract"},{"key":"16_CR39","unstructured":"Baca E, Bobes J, Canas F, et al. Cost-effectiveness analysis of long-acting injectable risperidone v. olanzapine and v. fluphenazine decanoate in treating schizophrenia [Spanish]. Rev Esp Econ Salud 2005; 4(5):273\u201385."},{"issue":"4","key":"16_CR40","doi-asserted-by":"crossref","first-page":"341","DOI":"10.2165\/00019053-200826040-00006","volume":"26","author":"M Knapp","year":"2008","unstructured":"Knapp M, Windmeijer F, Brown J, et al. Cost-utility analysis of treatment with olanzapine compared with other antipsychotic treatments in patients with schizophrenia in the pan-European SOHO study. Pharmacoeconomics. 2008;26(4):341\u201358.","journal-title":"Pharmacoeconomics"},{"issue":"4","key":"16_CR41","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1185\/03007995.2011.554533","volume":"27","author":"NM Furiak","year":"2011","unstructured":"Furiak NM, Ascher-Svanum H, Klein RW, et al. Cost-effectiveness of olanzapine long-acting injection in the treatment of patients with schizophrenia in the United States: a micro-simulation economic decision model. Curr Med Res Opin. 2011;27(4):713\u201330.","journal-title":"Curr Med Res Opin"},{"issue":"12","key":"16_CR42","doi-asserted-by":"crossref","first-page":"3341","DOI":"10.1185\/03007990802490512","volume":"24","author":"NC Edwards","year":"2008","unstructured":"Edwards NC, Pesa J, Meletiche DM, et al. One-year clinical and economic consequences of oral atypical antipsychotics in the treatment of schizophrenia. Curr Med Res Opin. 2008;24(12):3341\u201355.","journal-title":"Curr Med Res Opin"},{"issue":"1","key":"16_CR43","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/2191-1991-2-8","volume":"2","author":"AJ Garcia-Ruiz","year":"2012","unstructured":"Garcia-Ruiz AJ, Perez-Costillias L, Montesinos AC, et al. Cost-effectiveness analysis of antipsychotics in reducing schizophrenia relapses. Health Econ Rev. 2012;2(1):8.","journal-title":"Health Econ Rev"},{"issue":"16","key":"16_CR44","first-page":"1","volume":"7","author":"M Geitona","year":"2008","unstructured":"Geitona M, Kousoulakou H, Ollandezos M, et al. Costs and effects of paliperidone extended release compared with alternative oral antipsychotic agents in patients with schizophrenia in Greece: a cost effectiveness study. Ann Gen Psychiatry. 2008;7(16):1\u201312.","journal-title":"Ann Gen Psychiatry"},{"key":"16_CR45","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.schres.2011.03.033","volume":"130","author":"PG Barnett","year":"2011","unstructured":"Barnett PG, Scott JY, Rosenheck RA. How do clinical trial participants compare to other patients with schizophrenia? Schizophr Res. 2011;130:34\u20139.","journal-title":"Schizophr Res"},{"key":"16_CR46","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/j.1600-0447.2006.00980.x","volume":"116","author":"OS Niaz","year":"2007","unstructured":"Niaz OS, Haddad PM. Thirty-five months experience of risperidone long-acting injection in a UK psychiatric service including a mirror-image analysis of in-patient care. Act Psychiatr Scand. 2007;116:36\u201346.","journal-title":"Act Psychiatr Scand"},{"issue":"11","key":"16_CR47","doi-asserted-by":"crossref","first-page":"777","DOI":"10.2165\/11537680-000000000-00000","volume":"30","author":"C Carswell","year":"2010","unstructured":"Carswell C, Wheeler A, Vanderpyl J, et al. Comparative effectiveness of long-acting risperidone: a report of resource utilisation and costs in a 12\u00a0month mirror-image analysis. Clin Drug Investig. 2010;30(11):777\u201387.","journal-title":"Clin Drug Investig"},{"issue":"6","key":"16_CR48","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.jpsychires.2012.02.019","volume":"46","author":"HC Chang","year":"2012","unstructured":"Chang HC, Tang CH, Huang ST, McCrone P, Su KP. A cost-consequence analysis of long-acting injectable risperidone in schizophrenia: a one-year mirror-image study with national claim-based database in Taiwan. J Psychiatr Res. 2012;46(6):751\u20136.","journal-title":"J Psychiatr Res"},{"issue":"1","key":"16_CR49","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3109\/13651500903311821","volume":"14","author":"B Spill","year":"2010","unstructured":"Spill B, Konoppa S, Kissling W, et al. Long-term observation of patients successfully switched to risperidone long-acting injectable: a retrospective, naturalistic 18-month mirror-image study of hospitalization rates and therapy costs. Int J Psychiatry Clin Pract. 2010;14(1):53\u201362.","journal-title":"Int J Psychiatry Clin Pract"},{"issue":"1","key":"16_CR50","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/j.1600-0447.2006.00766.x","volume":"114","author":"CL Young","year":"2006","unstructured":"Young CL, Taylor DM. Health resource utilization associated with switching to risperidone long-acting injection. Act Psychiatr Scand. 2006;114(1):14\u201320.","journal-title":"Act Psychiatr Scand"},{"issue":"1","key":"16_CR51","doi-asserted-by":"crossref","first-page":"41","DOI":"10.2165\/00148365-200806010-00004","volume":"6","author":"JM Olivares","year":"2008","unstructured":"Olivares JM, Rodriguez-Martinez A, Buron JA, et al. Cost-effectiveness analysis of switching antipsychotic medication to long-acting injectable risperidone in patients with schizophrenia: a 12- and 24-month follow-up from the e-STAR database in Spain. Appl Health Econ Health Policy. 2008;6(1):41\u201353.","journal-title":"Appl Health Econ Health Policy"},{"issue":"2","key":"16_CR52","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/j.1600-0447.2009.01352.x","volume":"120","author":"D Taylor","year":"2009","unstructured":"Taylor D, Fischetti C, Sparshatt A, et al. Risperidone long-acting injection: a 6-year mirror-image study of healthcare resource use. Act Psychiatr Scanda. 2009;120(2):97\u2013101.","journal-title":"Act Psychiatr Scanda"},{"key":"16_CR53","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1192\/bjp.171.6.509","volume":"171","author":"M Knapp","year":"1997","unstructured":"Knapp M. Costs of schizophrenia. Br J Psychiatry. 1997;171:509\u201318.","journal-title":"Br J Psychiatry"},{"issue":"11","key":"16_CR54","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1002\/pds.978","volume":"13","author":"A Leal","year":"2004","unstructured":"Leal A, Rosillon D, Mehnert A, et al. Healthcare resource utilization during 1-year treatment with long-acting, injectable risperidone. Pharmacoepidemiol Drug Saf. 2004;13(11):811\u20136.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"9","key":"16_CR55","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1185\/03007990903149306","volume":"25","author":"JM Olivares","year":"2009","unstructured":"Olivares JM, Peuskens J, Pecenak J, et al. Clinical and resource-use outcomes of risperidone long-acting injection in recent and long-term diagnosed schizophrenia patients: results from a multinational electronic registry. Curr Med Res Opin. 2009;25(9):2197\u2013206.","journal-title":"Curr Med Res Opin"},{"issue":"Suppl. 5","key":"16_CR56","first-page":"15","volume":"67","author":"JP McEvoy","year":"2006","unstructured":"McEvoy JP. Risks versus benefits of different types of long-acting injectable antipsychotics. J Clin Psychiatry. 2006;67(Suppl. 5):15\u20138.","journal-title":"J Clin Psychiatry"},{"issue":"3","key":"16_CR57","first-page":"157","volume":"2","author":"L Ginnelly","year":"2003","unstructured":"Ginnelly L, Manca A. The use of decision models in mental health economic evaluation: challenges and opportunities. Appl Health Econ Health Policy. 2003;2(3):157\u201364.","journal-title":"Appl Health Econ Health Policy"},{"issue":"7","key":"16_CR58","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pmed.1000100","volume":"6","author":"A Liberati","year":"2009","unstructured":"Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. PLoS Med. 2009;6(7):1\u201328.","journal-title":"PLoS Med"}],"container-title":["Applied Health Economics and Health Policy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40258-013-0016-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40258-013-0016-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40258-013-0016-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,10]],"date-time":"2019-07-10T23:12:02Z","timestamp":1562800322000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40258-013-0016-2"}},"subtitle":["A Systematic Review of Economic Evaluations"],"short-title":[],"issued":{"date-parts":[[2013,3,14]]},"references-count":58,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,4]]}},"alternative-id":["16"],"URL":"https:\/\/doi.org\/10.1007\/s40258-013-0016-2","relation":{},"ISSN":["1175-5652","1179-1896"],"issn-type":[{"value":"1175-5652","type":"print"},{"value":"1179-1896","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,3,14]]}}}